Home StocksNATCOPHARM

NATCOPHARM Share PriceHealthcare

₹ 966.30

-17.85 (-1.81%)

as on 08 Jul 2026 at 15:57

Market Cap₹17,307 Cr

PE Ratio12.40

ROCE30.12%

2.7K

33.33% Buy (Based on 9 analysts)

Natco Pharma

NATCOPHARM Share PriceHealthcare

₹ 966.30

-17.85 (-1.81%) loss

as on 08 Jul 2026 at 15:57

2.7K

33.33% Buy (Based on 9 analysts)

Overview

News

History

Fundamentals

Investment Returns

Technicals

Financials

Balance Sheet

Cash Flow

Corporate Actions

Peers

Today Natco Pharma opened at 984.00 while its previous close was at 984.15. In todays trading session NATCOPHARM reached a high of 997.30 and low of 957.60. The average traded price for today is 976.62. The 50 DMA stands at 1,017.65 and 200 DMA is at 927.69. Looking at intraday trend, the stock is in Downtrend.

Get 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE.

Use Chart

NATCOPHARM Stock Performance

Markets Today

High

997.30

Low

957.60

Open at

984.00

Prev Close

984.15

Volumes

10,59,449

Avg Price

976.62

Lower Circuit

773.05

Upper Circuit

1,159.55

Last Traded Details

Quantity

150

Time

15:57:07

Price Movement

957.60997.30

0.91%

down side

up side

3.11%

Historical Performance

3 M High

1,226.80

3 M Low

839.00

1 Yr High

1,226.80

1 Yr Low

789.00

3 Yr High

1,639.00

3 Yr Low

667.80

5 Yr High

1,639.00

5 Yr Low

502.00

1-Year Performance

789.001,226.80

22.47%

down side

up side

21.23%

View In-Depth

NATCOPHARM Analyst Rating

Buy

Analysts have suggested that investors can
Buy this Stock

- By Refinitiv from 9 analysts

Buy

33.33%

Hold

33.33%

Sell

33.33%

Get forecast for Price, ROA & ROE based on analyst ratings.

Get Forecast

NATCOPHARM Latest News

View All

NATCOPHARM Share Price History

View In-Depth

NATCOPHARM Fundamentals

Company Valuation

Market Cap (₹ Cr.)

17,307

PE Ratio

12.40

PB Ratio

1.91

Dividend Yield

0.51%

ROE

24.74%

ROCE

30.12%

Book Value (₹)

514.83

Face Value (₹)

2.00

Analyse NATCOPHARM with 12+ custom fundamentals and financial ratios.

Analyse Now

Share Holding Pattern

Held By	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	49.56%	49.56%	49.48%	49.48%	49.42%
Domestic Institutional Investors (DII)	5.65%	5.82%	5.87%	5.39%	5.46%
Foreign Institutional Investors (FII)	17.49%	15.51%	14.09%	15.16%	17.37%
Public Investors	23.68%	25.22%	25.84%	25.38%	23.34%
Government	0.00%	0.00%	0.00%	0.00%	0.00%

Mar 2026
Dec 2025
Sep 2025
Jun 2025
Mar 2025

Promoters

49.42%

Domestic Institutional Investors (DII)

5.46%

Foreign Institutional Investors (FII)

17.37%

Public Investors

23.34%

Government

0.00%

View In-Depth

Natco Pharma Return Calculator

You have invested

Investment Period

Current value of ₹1,00,000 invested 5 years ago, as on today

₹ 0

Loss

₹ 1,00,000 (11.12%)

Invest Now

Note: Past profits do not guarantee future returns.

NATCOPHARM Investment Returns

Short Term

1 Week

3.76%

1 Month

11.29%

3 Months

-10.73%

6 Months

2.14%

9 Months

19.09%

Long Term

1 Year

-0.75%

2 Years

-19.16%

3 Years

41.82%

4 Years

52.56%

5 Years

-11.12%

In Short Term
In Long term

1 Week

3.76%

1 Month

11.29%

3 Months

-10.73%

6 Months

2.14%

9 Months

19.09%

View In-Depth

Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.

Start SIP

NATCOPHARM Technicals

Moving Averages

Classic

Exponential

Period	Simple	Signal
5-SMA	941.65	Bullish
10-SMA	924.93	Bullish
20-SMA	894.90	Bullish
50-SMA	1,017.65	Bearish
100-SMA	997.89	Bearish
200-SMA	927.69	Bullish

Technical Indicators

Indicator	Value	Action
RSI(14)	60.49	Neutral
ATR(14)	33.08	Volatile
STOCH(9,6)	80.45	Overbought
STOCH RSI(14)	97.94	Overbought
MACD(12,26)	17.03	Bullish
ADX(14)	23.16	Weak Trend

Summary of Technical Indicators for NATCOPHARM

View In-Depth

Margin on NATCOPHARM

Order Type	Margin to Pay	Leverage	Quantity	Trade Value	Margin Amount	Actions

*Calculated on NSE. Applicable on all exchanges. Margins are subject to change from time to time or may be withdrawn under volatile market conditions. Intraday Orders are square-off automatically at 03:19 pm on NSE / BSE or on hitting 80% of margin utilisation (whichever earlier).

NATCOPHARM Financials Summary

View By:

Consolidated

Standalone

Revenue

EBITDA

Net Profit

EPS

Revenue

In Crores

Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
1,287	1,391	1,463	705	817

NATCOPHARM Financials

Consolidated

Standalone

View byConsolidated

Standalone

Income Statement

In Cr

Quarterly Statement	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	1,287	1,391	1,463	705	817
Expenses	673	758	784	489	612
	614	633	679	217	205
Operating Profit	548	571	579	159	128
Operating Profit Margin %	45%	43%	42%	25%	17%
Other Income	66	62	100	58	78
Interest	10	3	13	10	11
Depreciation	98	58	52	46	50
	506	572	614	161	144
Tax %	20%	16%	16%	6%	-87%
Net Profit	406	480	518	151	269
EPS	23	27	29	8	15

Balance Sheet

In Cr

Yearly Balance Sheet	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	5,109	5,657	6,906	8,631	11,074
Fixed Assets	2,312	2,427	2,491	2,698	3,033
Current Assets	2,497	3,000	4,024	5,270	5,052
Capital Work in Progress	130	64	137	225	294
Investments	308	392	539	474	909
Other Assets	2,360	2,774	3,739	5,234	0
	5,109	5,657	6,906	8,631	11,074
Current Liabilities	710	683	973	944	1,681
Non Current Liabilities	135	101	80	75	172
	4,264	4,874	5,853	7,612	9,221
Reserve & Surplus	4,227	4,837	5,817	7,571	9,185
Share Capital	37	37	36	36	36
Minority Interest	0	0	0	5	0

Cash Flow

In Cr

Yearly Cash Flow	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Operating Activities	299	47	849	1,212	1,697
Investing Activities	-107	4	-465	-1,026	-1,437
Financing Activities	-186	35	-363	-247	-211
Net Cash Flow	6	85	21	-62	50

View In-Depth

Corporate Actions

Date	Corporate Action	Information
29th May 2026, Friday	Stock Result	Q4 FY 26-27 Results
18th Feb 2026, Wednesday	Dividend	Interim 3 Dividend of ₹1.5/share
12th Feb 2026, Thursday	Stock Result	Q3 FY 25-26 Results
20th Nov 2025, Thursday	Dividend	Interim 2 Dividend of ₹1.5/share
14th Nov 2025, Friday	Stock Result	Q2 FY 25-26 Results

The above dates are ex-dates.

View All

Check NATCOPHARM latest Company Filings, Investor Presentation & Conference Call details.

Read Now

NATCOPHARM Revenue Growth

All values are in Crores

Revenue

Profit

Loss

Financial Year	Revenue	Revenue Growth	Net Profit	Profit Growth
FY 2024-25	3,595	20.2%	1,096	41.62%
FY 2023-24	4,416	50.77%	1,850	105.09%
FY 2022-23	3,674	30.83%	1,307	358.02%
FY 2021-22	2,437	6.14%	637	-55.06%
FY 2020-21	1,862	-8.33%	139	-34.77%

Top Mutual Funds Invested in NATCOPHARM

Name	NAV	AUM	Weightage	1Y Return	3Y Return	5Y Return	Expense Ratio

NATCOPHARM Popular Brands

NATCOPHARM Similar Stocks

Stock Name	Price
S Sun Pharmaceutical	1,888.20-0.80%
D Divis Laboratories	6,755.00-0.24%
T Torrent Pharmaceuticals	4,866.40+0.20%
C Cipla	1,431.80-1.38%
Z Zydus Life Science	1,148.00-0.43%

View All

NSE Indices Today

NSE

BSE

Index Name	Price

View All

Top Gainers Today

Stock Name	Price

View All

Top Losers Today

Stock Name	Price

View All

Open IPOs

View All IPOs

Calculators

Brokerage Calculator

Margin Calculator

MTF Calculator

Stock Return Calculator

Stock Average Calculator

View All

What's New In The Market

View All

FAQs on NATCOPHARM

What is the share price of Natco Pharma?

Natco Pharma share price as of today is ₹ 966.30 as on 08 Jul 2026 at 15:57.

What is the 52W high and 52W low of Natco Pharma?

The 52W high of Natco Pharma is ₹ 1,226.80 and 52W low is ₹ 789.00 as of 08 Jul 2026 at 15:57.

What is the return on Natco Pharma share?

The past returns of Natco Pharma share are -

Past 1 year: -0.75%
Past 3 years: 41.82%
Past 5 years: -11.12%

What is the PE and PB Ratio of Natco Pharma?

The PE and PB ratio of Natco Pharma stands at 12.40 and 1.91 respectively as on 08 Jul 2026 at 15:57.

What is the EPS of Natco Pharma?

The EPS of Natco Pharma is 14.96 for the quarter ended Mar 2026 and 79.20 for the financial year 2025-26.

What is the shareholding pattern of Natco Pharma?

The shareholding pattern of Natco Pharma is as follows:

DIIs - 5.46%
FII - 17.37%
Promoters - 49.42%
Public Investors 23.34%
Goverenment - 0.00%

How to buy Natco Pharma shares online?

Yes, you can buy shares of Natco Pharma online by opening Demat account with Dhan.

How to buy Natco Pharma shares on Dhan?

If you are a Dhan user already, you can buy Natco Pharma stocks from Dhan Trading App or Web Trading Platform. If you are new to Dhan follow the below steps:

Download the Dhan App to Open a Demat Account
Navigate to the “Money Tab”
Add money to your account
Search for Natco Pharma share
Tap on “Buy”

With Dhan you can start a daily, weekly or monthly SIP in Natco Pharma.

How to buy Natco Pharma shares after market is closed?

You can easily buy the shares of Natco Pharma even after the markets are closed using the After Market Order feature on Dhan Trading App.

Invest & Trade with a Trading
Platform That's icon

Open your Dhan Account in minutes!

Explore | Sitemap

*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

We are doing so by giving you access to not just one but 6 products within the Dhan ecosystem:

Dhan App: The only online trading app you need for buying and selling equity, futures, options, commodity, and currency.
Dhan Web: Trade on the big screen across segments with our web trading platform.
Options Trader App: A dedicated option trading app built for India's F&O traders.
Options Trader Web: Love big screens and F&O trading? Use our web option trading platform.
Dhan + TradingView: The magic of Tradingview charts for free with the Lightning-Fast experience of Dhan on tv.dhan.co.
Connect to TradingView: Our Tradingview broker integration allows you to trade in Stocks, Futures, and Commodities directly from tradingview.com via Dhan.

This means that with Dhan, you'll be able to start:

Lakhs of users already trust Dhan for their online stock trading and investing needs. Dhan is growing rapidly because of the love we receive from SuperTraders and Long-Term Investors who acknowledge that the platform is innovating for them, building super useful features that help them do everything from investing in stock market to trading F&O like a pro on the Tradingview charts and much more.

While we are growing, we will always remember why we started building in the first place - you. Our user-first approach will always be at the heart of our philosophy. Come join us on this incredible journey!

Try it out, you can close your account at anytime using this link.

©2021-2026 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services and works closely with Raise Partners across services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered & Corporate Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104, Customer Care: 9987761000.

Details of client bank account

For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.

Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.

DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.

Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances. You may refer the website https://scores.sebi.gov.in/ for more information. You may also download the SEBI Scores app to log a complaint Android: https://play.google.com store apps sebiscores iOS: https://apps.apple.com app sebiscores.

Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit

Attention investors:

Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.

Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. Issued in the interest of the investors.

Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account. Raise Securities Private Limited (Dhan) does not engage in proprietary trading on its own account.

Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/

Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX

Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets